Table 2.

Patient characteristics by sentinel lymph node status

	SLN status					All patients
	Negative		Positive
	n	%r	n	%r	P	n	%c
All patients	226	87.9	31	12.1	-	257	100.0
Year of surgery					0.915
Before 2003	42	89.4	5	10.6		47	18.3
2003–2006	111	88.1	15	11.9		126	49.0
2007–2010	73	86.9	11	13.1		84	32.7
Age class, years					0.079
< 50	91	82.7	19	17.3		110	42.8
50–59	69	90.8	7	9.2		76	29.6
60+	66	93.0	5	7.0		71	27.6
Menopausal status					0.030
Premenopausal	99	83.2	20	16.8		119	46.3
Postmenopausal	127	92.0	11	8.0		138	53.7
Histology					0.177
Ductal	203	86.8	31	13.2		234	91.1
Lobular	8	100.0	0	-		8	3.1
Other	15	100.0	0	-		15	5.8
Grade					0.511
G1	36	87.8	5	12.2		41	15.9
G2	87	89.7	10	10.3		97	37.8
G3	83	84.7	15	15.3		98	38.1
Unknown	20	95.2	1	4.8		21	8.2
Subtype					0.387
Unknown	23	88.5	3	11.5		26	10.1
Luminal A	70	90.9	7	9.1		77	30.0
Luminal B (Ki67 ≥ 20%)	22	81.5	5	18.5		27	10.5
Luminal B (HER2 positive)	22	88.0	3	12.0		25	9.7
HER2 positive	66	90.4	7	9.6		73	28.4
Triple negative	23	79.3	6	20.7		29	11.3
Local treatment					0.206
Mastectomy w/o RT	49	81.7	11	18.3		60	23.3
Mastectomy w RT	27	87.1	4	12.9		31	12.1
Quadrantectomy w RT	150	90.4	16	9.6		166	64.6
Systemic treatment					< 0.001
Nil	109	93.2	8	6.8		117	45.5
ET	110	89.4	13	10.6		123	47.9
CT	5	35.7	9	64.3		14	5.4
CT+ET	2	66.7	1	33.3		3	1.2

Abbreviations: SLN, sentinel lymph node; RT, radiotherapy; ET, endocrine therapy; CT, chemotherapy.